PG-PS 10S (group A streptococcus)

• Cat.No.: COP29

Specification

• Cat. No.: COP29
• Description: PG-PS 10S consists of purified peptidoglycan-polysaccharide polymers which are isolated from the sonicated cell wall of Streptococcus pyogenes, Group A, D58 strain. The peptidoglycan is the primary immunogenic moiety. The polysaccharide, when bound to this peptidoglycan moiety, allows for the chronic inflammation seen in animal models by protecting this moiety from degradation. The PG-PS 10S is supplied as a white, opalescent liquid suspension in sterile 0.85% saline. The rhamnose concentration of the product is 3 to 6 mg/ml and the MW range of the product is 5 x 106 to 5 x 108 daltons.
• IntendedUse: PG-PS 10S is used in various animal models for induction of acute inflammatory responses which can evolve into a remittent, chronic, inflammatory response. Experimental chronic diseases induced by PGPS in rats include chronic, erosive, remittent arthritis, granulomatous enterocolitis (resembling Crohn's disease), granulomatous hepatitis, intestinal hemorrhage, carditis and vasculitis. PG-PS induces animal responses which are representative of naturally caused inflammatory disorders. PG-PS 10S is used in both the intraperitoneal model for chronic arthritis and the intramural model for gastrointestinal inflammation. These applications also include evaluations and studies of antiinflammatory drugs and therapies. One such model, the arthritic model in rats, is described below.
• Precautions: The PG-PS 10S material must be stored and handled in an aseptic manner to avoid product contamination. Such contamination may affect animal model results. For Research Use Only. Not for use in diagnostic procedures.
• Storage: 2 - 8°C. Discard any reagent which has become obviously contaminated or discolored.
• Instructions for Use: Procedure for Arthritic Rat Model Intra-peritoneal Injec-tion. Materials Provided: PG-PS 10S, 3 - 6 mg rham-nose/ml ; Materials Required: Lewis Strain Rats, female; 150 - 200 gm each; Sterile 0.85% saline; Balance; Vor-texer; Caliper; 1 ml syringes; 23 gauge needles1. Randomly divide the rats into control and assay groups as required for the model. Label each group of rats appropriately. Control groups are defined as those rats receiving saline (negative control), and those rat receiving PG-PS 10S (positive control) with no interven-tion or treatment such as anti-inflammatory drugs. Assay groups are defined as rats receiving PG-PS 10S with intervention.2. Weigh each rat in each group and determine the average body weight of each group. This average must be between 150 - 200 gm.3. Measure each rat's ankle (maximal lateral) individu-ally with a caliper to determine the baseline ankle measurement. Measure both left and right ankles. Each ankle should be measured 3 times and averaged.4. Vortex the PG-PS 10S for 30 seconds to thoroughly mix the material. Suspensions which appear to no longer be smooth or uniform (aggregated suspension) should be sonicated at low energy levels for 10-20 se-conds with a probe type sonicator prior to injection.5. Rats in the assay and positive control groups are injected with a total of 15 μgm of rhamnose/gm aver-age body weight (calculated in Step # 2 above). The injection must be prepared aseptically to avoid contam-ination. Calculate the volume of reagent to inject per rat.6. Anesthetize each rat in the assay and positive con-trol groups.
• Limitations of theProcedure: Certain animals may not respond to the PG-PS 10S injection and are termed non-responders. This is typically due to the placement of the 10S material,and is not reflective of the quality of the product. Typi-cally, less than 20% should be non-responders (in the positive control group) to consider the place-ment technique valid. Remove non-responders from the protocol after the initial 6 days post-injection and do not include this data in calculating averages or percent response.